Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Next Previous
Trial Profile

GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ticagrelor (Primary) ; Aspirin; Clopidogrel
  • Indications Acute coronary syndromes; Cardiovascular disorders; Coronary artery disease; Myocardial infarction; Stroke; Thrombosis
  • Focus Therapeutic Use
  • Acronyms GLOBAL-LEADERS

Most Recent Events

  • 28 Aug 2023 Results of post hoc analysis (n=14909) assessing to perform an external validation of our model for bleeding risk and to demonstrate its discriminative value in comparison with the PRECISE DAPT score, an acknowledged risk score, presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology.
  • 01 Jul 2022 Results (n=2115) of a sub-analysis comparing experimental antiplatelet arm with reference arm after PCI in patients experienced POCE at 2 years published in the Catheterization and Cardiovascular Interventions
  • 01 Sep 2020 Results of pre-specified per-protocol analysis presented at the ESC Congress 2020 - Annual Congress of the European Society of Cardiology.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top